Vaxcyte (PCVX) Accumulated Expenses (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Accumulated Expenses data on file, last reported at $30.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 16.15% year-over-year to $30.2 million in Q1 2026; TTM through Mar 2026 was $30.2 million, a 16.15% increase from a year earlier, with the FY2025 full-year figure at $31.1 million, up 6.68% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $30.2 million, down from $31.1 million in the prior quarter.
• Over the last five years, Accumulated Expenses for PCVX reached as high as $54.2 million in Q1 2024 and fell as low as $4.4 million in Q2 2023.
• Historically, Accumulated Expenses has averaged $19.6 million across 5 years, with a median of $15.4 million in 2022.
• Across the five-year window, Accumulated Expenses surged 602.2% in 2022 and sank 55.37% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $15.4 million in 2022, then retreated by 28.09% to $11.1 million in 2023, then surged by 163.41% to $29.1 million in 2024, then climbed by 6.68% to $31.1 million in 2025, then retreated by 2.64% to $30.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $30.2 million in Q1 2026, $31.1 million in Q4 2025, and $16.8 million in Q3 2025.